Recht, Michael

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine

Hemophilia Treatment and ResearchPlatelet Disorders and Treatments

Cited by 1,950

Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B

Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine

Hemophilia Treatment and ResearchVirus-based gene therapy research

Cited by 1,273

Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia

GERSTNER, G., DAMIANO, M. L., TOM, A., WORMAN, C., SCHULTZ, W., RECHT, M., & STOPECK, A. T. (2009) · Haemophilia

Hemophilia Treatment and ResearchBone health and osteoporosis research

Cited by 148

Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII

RECHT, M., NEMES, L., MATYSIAK, M., MANCO‐JOHNSON, M., LUSHER, J., SMITH, M., MANNUCCI, P., HAY, C., ABSHIRE, T., O’BRIEN, A., et al. (2009) · Haemophilia

Hemophilia Treatment and ResearchPlatelet Disorders and Treatments

Cited by 92